Abstract
Overview
Introduction
The diabetes epidemic has contributed in the growth of the antidiabetics
market the past few years. Since the prevalence of diabetes continues to
increase, the market will further expand. While early therapy is dominated by
generically available agents, and the later stages by insulin, the number of
unmet needs in the diabetes treatment, warrants that novel agents will have a
place in the market.
Scope
- Country specific event-driven sales forecasts for the period 2006-15 for
the US, Japan, France, Germany, Italy, Spain and the UK and Global overview.
- Patient potential and prescribing trends overview of the antidiabetics
market based on historical sales data and future key events.
- Profiles of the country and market specific issues which will impact
future sales in the market including generic erosion and class switching.
- Case studies presenting the role that novel agents are likely to play and
the balance between issues and opportunities in the diabetes market
Report Highlights
Demographic trends will lead to increasing patient population. The
antidiabetics market is set to continue increasing, driven by the dramatic
increase in the prevalence of diabetes in the major markets. Additionally, the
rising age of the population across all developed regions is creating an
increased burden on health service providers and payers.
The highest selling drug classes in the antidiabetics market are heavily
genericized and thus will not generate the revenues needed for growing the
market. Additionally, TZDs, one of the most lucrative classes, will face
patent expiries in the coming decade. These events is expected to be
counterbalanced by the introduction of novel agents.
The diabetes market is characterized by high unmet need and treatment issues.
However, these issues along with radical changes on the understanding of
diabetes, have created an environment rich in opportunity. We expect that the
growth of the diabetes market will be driven by the exchange of older, cheaper
drugs for new more expensive agents.
Reasons to Purchase
- Quantify future size and scope of the diabetes market and potential for
new products
- Analyze options to expand commercial potential through pursuit of new
indications
- Formulate successful launch strategies in a highly competitive market
View Cart
